Free Republic

[H/T Countrecount]This video is approved by Doctors Pierre Kory and Paul Marik and many others. The video is NOT approved by the FDA, the CDC, the NIH, CNN, or the White House. Producer: Mikki Willis, Length: 15 min.Steve Kirsch5 hr agoIvermectin: The Truth is an amazing film, less than 15 minutes long! I highly recommend this film. Watch it and share it.Pierre Kory, Paul Marik, Peter McCullough, Robert Malone, Chris Martenson, Richard Bartlett, and Mike Yeadon all appear. My name appears briefly at 11:45 in the video. Still trying to get that debate with the mainstream “experts.” The Ivermectin film...

It took about 4 days for David Boulware, MD, MPH, to write the FDA emergency use authorization (EUA) application for fluvoxamine. Yes, a doctor wrote an EUA application -- a task that has typically been relegated to pharmaceutical companies -- and yes, it was for a generic drug that physicians could technically prescribe off-label. But Boulware, of the University of Minnesota, who is involved in a trial that's investigating fluvoxamine and other repurposed drugs -- along with a handful of other doctors and researchers -- took it upon themselves to apply because they believe the data substantiate its use in...

More evidence of corruption at the NIH. I couldn't find a scientist that would be willing to defend the NIH's recommendation in a recorded interview. The NIH recently acknowledged that fluvoxamine completed a Phase 3 study showing it works that was published in the Lancet Global Health. The study noted that “there was one death in the fluvoxamine group and 12 in the placebo group for the per-protocol population (OR 0·09; 95% CI 0·01–0·47).” In plain English, if you started the drug early (shortly after symptoms) and you took at least 80% of the doses you were told to take...

AbstractDoctors today are driven by what the NIH says, not science. The NIH ignores everything that isn't big pharma.Example: The Pfizer 6-month trial showed no all-cause mortality benefit; in fact, if anything, it showed that the vaccine killed more people than it saved. Sure, one COVID life was saved per 22,000 fully vaxed, but the all-cause mortality strongly favored the placebo (21 died in vaccine group vs. 17 in placebo). Doctors rush to recommend it. Nobody is skeptical.Fluvoxamine on the other hand actually demonstrated a 12 times reduction in all-cause mortality in the Phase 3 trial. SNIPWelcome to 2021 where...

He’s also publicly railed against what he claims is a campaign against drugs like fluvoxamine and ivermectin. And, according to three members of CETF’s scientific advisory board, he put pressure on them to promote fluvoxamine for clinical use without conclusive data that it worked for covid. More recently, he’s adopted extremist positions on covid vaccines, which he alleges are “toxic.” He has claimed that one in 1,000 people who have received mRNA vaccines have died as a result, and even claimed the vaccines “kill more people than they save” at an FDA public forum, which was first reported by the...

A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus. Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies. They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation. The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill...

The drug, which costs roughly 29p per tablet, was trialled on nearly 741 people who tested positive within seven days and had underlying health conditions. Patients were given a daily course of two pills for 10 days. Of those given the medication, 79 (10.6 per cent) needed hospital care compared to 15.7 per cent in the placebo group. Writing in the paper, the researchers said their analysis showed the pills cut the risk of hospitalisation by 32 per cent. Fluvoxamine works by boosting the amount of serotonin in the brain, which can help to boost someone's mood. But the hormone...

First hydroxychloroquine, now ivermectin, is the hated deadly drug de jour, castigated by the medical establishment and regulatory authorities. Both drugs have been around for a long time as FDA-approved prescription medications. Yet now we are told they are as deadly as arsenic. As a physician, I am certainly aware of ivermectin but don’t recall ever writing a prescription for it in my 30+ years’ medical career. Ivermectin is an anthelmintic, meaning it cures parasitic infections. In my world of ophthalmology, it is used on occasion for rare parasitic or worm infections in the eye. Ivermectin was FDA approved in...

An inexpensive anti-depressant curbed the number of COVID-19 patients ending up in hospital by 30 per cent, making it a potential breakthrough treatment for a virus that continues to spread widely, a Canadian-led clinical trial is reporting. If confirmed by more research, the drug, fluvoxamine, would be one of the most effective and convenient to treat the virus outside of pricey new “monoclonal antibodies.” They typically have to be administered in a hospital, as opposed to a pill taken orally at home. Fluvoxamine is given early in the course of the disease, potentially staving off more severe outcomes and their...

Key Points Question Does fluvoxamine, a selective serotonin reuptake inhibitor and σ-1 receptor agonist, prevent clinical deterioration in outpatients with acute coronavirus disease 2019 (COVID-19)? Findings In this randomized trial that included 152 adult outpatients with confirmed COVID-19 and symptom onset within 7 days, clinical deterioration occurred in 0 patients treated with fluvoxamine vs 6 (8.3%) patients treated with placebo over 15 days, a difference that was statistically significant. Meaning In this preliminary study, adult outpatients with symptomatic COVID-19 treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over 15 days; however, determination of clinical efficacy...